Introduction
Fertilization failure after ICSI still occurs in 3-5% of total ICSI cycles (Bhattacharya et al., 2013) . Experiencing fertilization failure is a distressing event (Rockliff et al., 2014) , which not only prematurely ends the current treatment cycle, but offers little perspective for future treatments. The etiologies underlying fertilization failure after ART have been repeatedly investigated. The ultrastructural analysis of oocytes that failed to fertilize after conventional IVF or ICSI have demonstrated that events, such as aberrant meiotic spindle configuration or defective sperm nuclear decondensation are associated with an impaired progress of the oocyte activation, defining this as main the cause of fertilization failures after ICSI (Rawe et al., 2000; Combelles et al., 2010) .
Oocyte activation in mammals coincides with a series of spatiotemporal intracytoplasmic calcium (Ca 2+ ) oscillations, evoked by the sperm upon release of a soluble factor phospholipase C zeta (PLCζ) (Swann and Lai, 2016) . PLCζ promotes the production of inositol trisphosphate (IP 3 ) which, further downstream, stimulates Ca 2+ discharge from the endoplasmic reticulum through its cognate receptor (IP 3 R1) (Wakai et al., 2013) . These Ca 2+ changes initiate a complex signaling cascade leading to meiotic alleviation. Given the pivotal roles that both oocyte and sperm-related factors play during oocyte activation, deficiencies associated either with the oocyte's Ca 2+ releasing machinery, such as IP 3 receptors (Ajduk et al., 2008) or PLCζ (Kashir et al., 2012; Escoffier et al., 2015) are likely to result in fertilization failures (Yeste et al., 2017) . Mouse based assays are commonly used to study sperm activation potential in patients experiencing ICSI failures (Rybouchkin et al., 1995; Heindryckx et al., 2005; Yoon et al., 2008) . The mouse oocyte activation test (MOAT) is an established diagnostic test performed in patients participating in our fertility program to help decide whether to use assisted oocyte activation (AOA) in subsequent ICSI cycles (Heindryckx et al., 2005; Vanden Meerschaut et al., 2012) . MOAT involves the injection of human sperm into mouse oocytes to determine sperm activation capacity. Hence, MOAT allows classifying patients into three groups in comparison to fertile control samples (Heindryckx et al., 2005) , from low to high activation potential: MOAT 1 (sperm-related activation deficiency), MOAT 2 (diminished sperm activation capacity) and MOAT 3 (normal sperm activation capacity, hence suspected oocyte-related oocyte activation deficiencies).
The benefit of AOA is particularly evident in cases experiencing ICSI failures with diminished MOAT activation rates (Vanden Meerschaut et al., 2012; Kuentz et al., 2013 as a novel strategy to reveal the presence of human sperm activation deficiencies in patients who experienced ICSI failures and demonstrated their capacity to activate mouse oocytes, particularly cases with slightly reduced MOAT (high range of MOAT 2) or normal MOAT (MOAT 3). Furthermore, the diagnostic accuracy of heterologous (M-OCA) and homologous (H-OCA) assays based on the response to ICSI-AOA treatment was evaluated.
Materials and Methods
Participants and study design A total of 16 male patients (37.1 ± 5.6 years old) that consulted our center between January 2009 and February 2017 regarding failed or low fertilization (<33.3%) after ICSI (Vanden Meerschaut et al., 2012) were randomly selected after signing a written informed consent form. All participants underwent MOAT before medical counseling for ICSI-AOA in a following treatment. AOA was advised following the algorithm described by . MOAT classifies the sperm activation potential based on the percentage of oocytes at 2-cell stage as follows: MOAT 1 ≤ 20%, MOAT 2 from 21 to 84%, MOAT 3 ≥ 85% oocytes activated after heterologous ICSI. The present study includes cases with activation rates from 68-96%. All patients were analyzed by M-OCA after medical consultation. Moreover, 11 out 16 patients who underwent AOA treatment in our center were further analyzed by H-OCA. Of note, patients were blindly assigned for further Ca 2+ analysis prior to obtaining the clinical outcome of ICSI-AOA.
Control sperm samples were donated after signing a written informed consent by patients with proven normal fertilization potential who participated in our fertility program.
Source and culture of human oocytes
Human oocytes discarded from IVF treatments were used. Oocytes were donated by patients <37 years old undergoing controlled ovarian hyperstimulation for IVF/ICSI treatments in our fertility program between October 2014 and August 2016 after signing a written informed consent. Oocytes were collected at one of three stages of maturation: in vivo matured metaphase II (MII) oocytes with smooth endoplasmic reticulum aggregates (SERa), in vitro matured (IVM) oocytes retrieved at prophase I (germinal vesicle, GV) or IVM oocytes retrieved at metaphase I (MI). To allow in vitro maturation, oocytes at GV stage were cultured for 24 h, and oocytes at Metaphase I (MI) were cultured for 3 or 24 h, as described elsewhere (Nikiforaki et al., 2014) . Oocytes were vitrified only at MII stage following the manufacturer's protocol (Irvine Scientific, USA) and using an open support for vitrification (Cryotop ® , Kitazato, Japan). Before ICSI, oocytes were warmed following manufacturer's instructions (Irvine Scientific, USA), and randomly assigned to the study and the control groups. Oocytes were cultured under paraffin oil at standard culture conditions (37°C in 6% CO 2 and 5% O 2 ) prior to Ca 2+ imaging.
Source and culture of mouse oocytes
Metaphase II oocytes were collected from 6 to 10-week-old B6D2F1 hybrid female mice following follicular hyperstimulation . Oocyte collection was performed 14 h following hCG (Chorulon ® , Intervet, Boxmeer, The Netherlands) injection. Further manipulations were performed in HEPES buffered potassium simplex optimized medium (KSOM-HEPES) prepared in-house, supplemented with 4 mg/ml bovine serum albumin (BSA, Calbiochem, Belgium). Denudation of cumulus cells was performed by a brief exposure to 200 IU/ml hyaluronidase. Oocytes were cultured in KSOM containing 4 mg/ml BSA under paraffin oil at standard culture conditions prior to Ca 2+ imaging.
Oocyte preparation for Ca 2+ imaging
Before ICSI, mouse and human MII oocytes were loaded with a ratiometric Ca 2+ -sensitive dye. Mouse oocytes were incubated in KSOM containing fura-2 acetoxymethyl-ester (Invitrogen, Belgium) while human oocytes were incubated in cook cleavage (CC) (Cook Ltd, Ireland) medium containing fura-PE3-acetoxymethyl-ester (Teflabs, Texas, USA) both at 7.5 μM and under standard culture conditions for 30 min. Oocytes were extensively washed in culture media prior to microinjection with human sperm.
Sperm preparation for ICSI
Frozen control and patient sperm samples were warmed at room temperature (RT) for 15 min and sperm selection was further performed by a swim-up method (Mortimer and Mortimer, 1992) or manually selected under an inverted light microscope after the first washing step in samples showing <5 million sperm/ml. 
ICSI
Mouse ICSI was performed according to Vanden using piezo electrical pulses as described by Yoshida ). Sperm was pretreated with lyso-lecithine (2 mM) to allow acrosome digestion before performing piezo-ICSI. Human oocytes were microinjected following a standard ICSI protocol, performed at 37°C. Of note, sperm were not pre-treated with lyso-lecithine prior to human ICSI.
Ca 2+ imaging
Total recording period was established at 2 h for M-OCA (Vanden Meerschaut et al., 2013) and 10 h for H-OCA (Nikiforaki et al., 2014 spikes, (+) 1-2, (++) 3-9 and (+++) ≥10 (Fig. 1) . We further defined the term 'oscillatory activity' as the presence of at least one Ca 2+ spike during the recording period. Finally, the activation potential per sperm sample was scored using the product A × F (AU) determined from the Ca 2+ spiking pattern.
Statistical analyses
Distribution of the frequency patterns, amplitudes and durations (presented as SEM) were analyzed applying a Kruskal-Wallis test for independent samples with a significance of P < 0.05. Oscillatory activity (presented as %) was analyzed by t-test (Statistical Package for the Social Sciences (SPSS ® Statistics 24, IBM Corp., NY, USA). EasyROC: webtool for receiver operating characteristic (ROC) curve analysis (version 3.1) was used for analyzing the diagnostic test accuracy based on AOA outcomes with a defined confidence interval of 90% by non-parametric Mann-Whitney test for SE stimulation using a Bonferroni correction for multiple comparisons.
Ethical approval
This study was approved by the Ghent University Hospital Institutional Review Board (reference: B670201423110). Animal studies were approved Mouse oocyte Ca 2+ analysis (M-OCA) outcome: Patients classified as MOAT group 2 revealed a slightly diminished oscillatory activity (66.4%), with no significant difference compared to the control group (91.2%) (P value = 0.142). Distribution of frequency pattern between MOAT group 2 patients and the control group was similar in categories from 0 to '++'. However, the proportion of oocytes showing ≥10 Ca 2+ oscillations/2 h (+++) was significantly lower (P = 0.02) compared to the control. Results of MOAT group 3 showed that the oscillatory activity (79.3%) and the distribution of frequency pattern were similar to the control group (P > 0.05).
(ii) Human oocyte Ca 2+ analysis (H-OCA) outcome:
Patients classified as MOAT group 2 revealed a prominent decrease in oscillatory activity (5.4%) and frequency of Ca 2+ oscillations, with significant differences in the distribution of frequency pattern compared to MOAT group 3 and control group. Mean oscillatory activity (%) of MOAT 2 and 3 group compared to the control group were compared by an independent samples t-test. Distribution of frequency pattern across MOAT groups 2 and 3, and control group were was compared by an independent-samples Kruskal-Wallis test. *Significance level P < 0.05.
by the Ghent University Hospital Ethical Committee for Laboratory Animals (reference: ECD number: 15/56).
Results
Mouse and human oocyte Ca 2+ analysis in patients experiencing ICSI failures
The sperm-induced Ca 2+ oscillatory profile was evaluated in patients showing moderate (MOAT 2, n = 9, 78.3 ± 6%) to normal (MOAT 3, n = 7, 90.0 ± 4%) sperm activation capacity. The ability of sperm to generate normal Ca 2+ response activity was first studied by M-OCA.
Sperm from MOAT 2 patients triggered what we define as 'oscillatory activity' (≥ 1 Ca 2+ spike/recording period), in 66.4% of the oocytes compared to 91.2% in the control group (Fig. 2) . The frequency analysis furthermore demonstrated a significantly reduced percentage of oocytes in the high frequency range (at least three spikes, i.e. classes '++' or '+++') compared to the control group (Fig. 2) . The oscillatory activity in MOAT 3 patients was 79.3%, i.e. intermediate between MOAT group 2 and the 91.2% in the control group; none of the subcategories ('+', '++' or '+++') were significantly different between both groups (Fig. 2) . In a next step, 11 out of 16 patients were selected for an additional H-OCA analysis. First, to characterized the total Ca 2+ response pattern elicited by human sperm in human oocytes we used three fertile control sperm samples ( Supplementary Fig. S1 ). Strikingly, human oocytes microinjected with sperm from patients classified as MOAT 2 (n = 6; 77.6 ± 6%), had a prominently lower oscillatory activity amounting to 5.4% (at least one Ca 2+ spike), compared to the 91.3% observed in the control group (Fig. 2) . Frequency analysis in MOAT 2 demonstrated 0% distribution in the high frequency '+++' group compared to 21.7% in control; 94.5% showed the absence of oscillatory activity ('0') compared to 8.7% in control ( Fig. 2 ; Supplementary  Table S2 ). In contrast, MOAT 3 patients (n = 5; 90.0 ± 4%) had an oscillatory activity comparable to the control group ( Fig. 2 ; Supplementary Table S2 ). The distribution of frequency patterns in patients from MOAT group 3 was also comparable to the controls.
Diagnostic accuracy of mouse and human oocyte Ca 2+ analysis for the response to ICSI-AOA We evaluated the diagnostic accuracy of oocyte Ca 2+ analysis tests for predicting AOA outcome, using the amplitude × frequency (A × F) scores calculated by M-OCA and H-OCA in a total of 11 patients. Plotting A × F values against fertilization rates after ICSI-AOA shows that abnormal A × F scores are associated with favorable AOA outcomes (Fig. 3) . Therefore, we assumed that AOA would not have a further benefit in cases with normal A × F values. As a result, M-OCA and H-OCA A × F scores calculated in the study group may define a threshold value associated with abnormal fertilization rates after ICSI-AOA. Consequently, we determined cut-off points by calculating the Youden's index ( Supplementary Fig. S2 ). A × F values associated with abnormal sperm activation capacity were estimated ≤6.72 AU for M-OCA and ≤0.6 AU for H-OCA. M-OCA identified 5 out of 11 patients with abnormal sperm activation capacity. H-OCA reclassified two patients, yielding 7 out of 11 patients with abnormal sperm activation capacity (Fig. 3) . Briefly, Patient 7 had complete absence of Ca 2+ oscillations in the H-OCA test. Similarly, Patient 10 had a reduced H-OCA A × F score of 0.6 AU ( Table I ). The 5 remaining cases with abnormal sperm activation capacity revealed by M-OCA, also showed extremely low Ca 2+ oscillatory responses with A × F scores estimated between 0.0 to 0.3 AU in human oocytes (Table I) . We further analyzed several properties of the A × F score to identify patients that could potentially benefit from AOA treatment using formulations to determine sensitivity, specificity and accuracy of the diagnostic test (Supplementary Table S1 ). Sensitivity of M-OCA was calculated as 0.75 (CI 90%: 0.19-0.99) (Table II) with three cases showing abnormal Ca 2+ oscillation activity out of a total of four cases with successful fertilization after ICSI-AOA (Fig. 3) . Interestingly, H-OCA revealed a sensitivity of 1.00 (CI 90%: 0.39-1) ( release activity attained a normal fertilization rate after ICSI-AOA (Fig. 3) . Moreover, M-OCA had a specificity of 0.71 (CI 90%: 0.29-0.96) (Table II) , showing the presence of two cases with abnormal Ca 2+ release activity without further benefit from ICSI-AOA.
H-OCA revealed a specificity of 0.57 (CI 90%: 0.18-0.90) (Table II) ; with four out of seven cases with abnormal Ca 2+ release activity which did not respond favorably to ICSI-AOA treatment (Supplementary data, Table S1 ). We further calculated the accuracy for M-OCA and H-OCA, which was estimated separately as 0.73 for each of the tests (Table II) .
Discussion
We evaluated whether the use of human oocytes would allow the discrimination between sperm or oocyte-related activation deficiencies in patients experiencing fertilization failures after routine ICSI and whose sperm were capable of activating mouse oocytes. Patients showing slightly diminished capacity of activating mouse oocytes (MOAT 2) revealed abnormal Ca 2+ oscillatory patterns during mouse oocyte activation. Interestingly, the six MOAT 2 patients, who were further analyzed by H-OCA, showed a pronounced decrease in Ca 2+ spiking activity in human oocytes. In support of previous findings, M-OCA revealed abnormal Ca 2+ profiles in patients from MOAT group 2, confirming that sperm-related activation deficiencies, rather than oocyte deficiencies, are responsible for fertilization failures in these cases . The present study revealed for the first time that sperm from patients showing reduced MOAT and M-OCA outcomes, are totally incapable to induce Ca 2+ oscillations in human oocytes. Fertilization failures experienced by patients with normal capacity for activating mouse oocytes (MOAT 3) were initially thought to be associated with oocyte-related oocyte activation deficiencies (Heindryckx et al., 2005 Clinical outcome: ICSI-AOA restored fertilization rates to normal in four out of seven patients with abnormal H-OCA A × F score. The four patients achieved a pregnancy after embryo transfer. Additionally, P2, who showed H-OCA A × F score = 0 AU and fertilization rate after ICSI-AOA of 18.8%, also achieved a pregnancy. 2pn, two pronuclei/diploids; MII, Metaphase II; MOAT, mouse oocyte activation test; M-OCA, mouse oocyte calcium analysis. H-OCA, human oocyte calcium analysis; AOA, assisted oocyte activation. (*) H-OCA was performed in patients who underwent AOA in our center (n = 11).
Reduced sperm activation potential, particularly in MOAT 1 patients, was previously correlated with favorable responses to ICSI-AOA (Heindryckx et al., 2008 , Vanden Meerschaut et al., 2012 . Still, the real benefit of the ICSI-AOA treatment in patients from MOAT groups 2 and 3 could not be clearly established. Our analysis reveals that Ca 2+ analysis can be used to predict fertilization success after ICSI-AOA, with H-OCA yielding higher sensitivity than M-OCA to detect the presence of human sperm activation deficiencies. The increase in sensitivity of H-OCA over M-OCA results from the absence of cases with normal sperm activation capacity after H-OCA, and hence favorable responses after ICSI-AOA. However, the success of the treatment will be limited to an estimated 57% of the cases presenting with abnormal H-OCA. Interestingly, the non-responding cases will be identified subsequently at the occasion of ICSI-AOA treatment, allowing them to be classified as having an additional oocyte-related oocyte activation deficiency (Fig. 4) . Overall, M-OCA and H-OCA showed similar capacity to allocate cases according to ICSI-AOA response. Here, it is interesting to note that H-OCA detected the incapability of human sperm to induce any or few Ca 2+ events in cases which showed the ability of generating Ca 2+ responses and subsequent oocyte activation in mouse oocytes. In our opinion, H-OCA reveals a clear cut off in the capacity of sperm to generate Ca 2+ responses, which supports the use of human oocytes as the most optimal test for the study of sperm activation potential. H-OCA data showed that, four out of the seven cases with reduced A × F score experienced an improvement in fertilization rate after ICSI-AOA, with four successful pregnancies achieved to term. Intriguingly, ICSI-AOA did not overcome failed fertilization in the three cases out of the seven diagnosed with sperm activation deficiencies by all three functional tests (MOAT, M-OCA and H-OCA). As previously mentioned, in these three cases we suspect the presence of an oocyterelated oocyte activation deficiency in addition to a sperm activation incapability (Fig. 4) . Given that our department is a reference center for patients experiencing fertilization failure, we may have identified a higher proportion of cases with a combined sperm-oocyte factor in the present study. In our experience, couples suffering from suspected combined sperm-oocyte factors require particular attention. Patients experiencing fertilization failures are frequently redirected to gamete donation programs. Our findings indicate that identifying sperm activation deficiencies could be important in making an informed decision regarding the use of donor oocytes or sperm in future treatments. Our data support that ICSI-AOA should be applied in patients with diagnosed sperm activation deficiencies, in this case irrespective of the origin of the oocytes (Fig. 4) . Our study further diagnosed 4 out of 11 cases with normal H-OCA A × F scores who experienced ICSI failure after AOA. Since all four patients showed the capacity of generating Ca 2+ oscillations in mouse, and most importantly in human oocytes, experiencing a failure in fertilization after ICSI-AOA points to the presence of a sole oocyte-related activation deficiency. These observations indicate that H-OCA can detect the cases who would not benefit from the Ca 2+ replacement induced by Ca 2+ ionophores during AOA procedure. In this regard, these cases would be candidates for participating in oocyte donation programs (Fig. 4) . We hypothesize that the mechanisms involved in supporting Ca 2+ oscillatory activity, such as IP 3 Rs or plasma membrane Ca 2+ ATPases (PMCAs), may not be directly responsible for the oocyte activation failure (Yeste et al., 2016) . Further investigations are urgently needed to develop AOA techniques aimed at tackling failed fertilization associated with oocyte-related oocyte activation failure. It is worth mentioning that procedures as IVM and cryopreservation have a slight impact on Ca 2+ oscillatory patterns, with, for instance, vitrified/warmed oocytes showing variations in amplitudes and frequencies when compared to their fresh counterparts (Nikiforaki et al., 2014) . Similarly, the presence of SERa in MII oocytes have a moderate effect on the Ca 2+ oscillatory response (De Gheselle et al., 2014) .
However, accumulating evidence supports the activation competence of these oocytes, with fertilization rates comparable to their fresh counterparts Rienzi et al., 2012) . Moreover, sperm cryopreservation also showed to have an influence on PLCz content (Kashir et al., 2011) . Since reduced levels of PLCz have been associated with impaired fertilization (Heytens et al., 2009) , it is worth taking into account that our results might not fully reflect the sperm activation capacity in our control and study groups. Cases with abnormal Ca 2+ response activity experiencing successful fertilization after ICSI-AOA divided by all cases experiencing successful fertilization after ICSI-AOA 3/(3 + 1) = 0.75 4/(4 + 0) = 1
Cases with normal Ca 2+ response activity which did not respond favorably to ICSI-AOA treatment divided by the total of cases which do not show further benefit from ICSI-AOA treatment 5/(5 + 2) = 0.71 4/(4 + 3) = 0.57
Cases with expected responses to ICSI-AOA (abnormal A × F score associated with normal fertilization after AOA and normal A × F score associated with failed fertilization after ICSI-AOA) divided by the total of cases studied (3 + 5)/11 = 0.73 (4 + 4)/11 = 0.73 specific equipment to monitor fluorescence changes over time. Interestingly, free cytoplasmic Ca 2+ oscillations have been correlated with cytoplasmic movements observed in oocytes during fertilization (Ajduk et al., 2011) . These cytoplasmic contractions, provoked by the polymerization of actin-myosin proteins, can be monitored by regular light microscopy, as shown already in mouse (Ajduk et al., 2011) and human (Swann et al., 2012) studies. These observations define a paradigm for the study of the early events of fertilization which could be feasibly adopted in IVF laboratories due to the emergence of timelapse imaging technologies (Freour et al., 2015) . In this regard, the present data provide an important template of the Ca 2+ signature observed during human fertilization in cases with normal, low and failed fertilization after conventional ICSI. The use of Ca 2+ ionophores for human ICSI-AOA has resulted in normal fertilization rates (Ebner et al., 2015) , subsequent pregnancies (Heindryckx et al., 2005) and healthy livebirths (D'haeseleer et al., 2014; Vanden Meerschaut et al., 2014a , 2014b Sfontouris et al., 2015; Miller et al., 2016) . Nevertheless, safety concerns remain regarding the use of Ca 2+ ionophores to induce oocyte activation (Santella and Dale, 2015; van Blerkom et al., 2015) , which is generated by a single and high Ca 2+ transient rather than the natural series of Ca 2+ oscillations. Moreover, specific Ca 2+ signatures during oocyte activation would likely have an impact on cellular events observed during oocyte activation (Ducibella et al., 2002) , on the subsequent embryonic development (Ozil, 1998; Ozil et al., 2006; Ducibella and Fissore, 2008) and they are possibly associated with variations in gene expression profiles , Rogers et al., 2006 . However, the efficiency of Ca 2+ ionophores to induce fertilization is supported by findings that described that mammalian fertilization could be mediated by the total summation of the individual Ca 2+ spikes rather than by specific patterns (Ozil et al., 2005; Tóth et al., 2006) . Further investigations are required to elucidate the effect of Ca 2+ oscillation pattern on pre-and post-implantation events, and most importantly on the off-spring. We showed the importance of diagnosing sperm-related activation capacity prior to the application of ICSI-AOA in patients experiencing ICSI failures. H-OCA is the most sensitive diagnostic test to study human sperm activation potential, and in combination with fertilization outcomes after ICSI-AOA, H-OCA identifies cases with suspected oocyte-related activation deficiencies. Further research is needed to explore oocyte factors associated with failed fertilization and possible treatments to restore fertilization in this challenging group of patients.
Supplementary data
Supplementary data are available at Human Reproduction online.
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